导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.49% | 2822/4773 |
| 近一周 | -1.22% | 1836/5465 |
| 近一月 | -1.17% | 1053/5421 |
| 近一季 | 0.51% | 903/5231 |
| 近半年 | 0.57% | 1286/4920 |
| 近一年 | 2.30% | 2303/4394 |
| 近两年 | 38.61% | 1962/2954 |
| 近三年 | 25.47% | 1288/2253 |
| 成立以来 | 29.04% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-6.04% 4013/4961 |
7.51% 2696/5312 |
- - |
- - |
| 2025 | 16.08% 2488/4813 |
-0.43% 2247/3635 |
2.82% 1329/4076 |
10.66% 3261/4524 |
2.46% 946/4813 |
| 2024 | 17.79% 653/3463 |
3.33% 593/2808 |
-0.15% 694/3014 |
16.13% 1530/3129 |
-1.70% 1796/3463 |
| 2023 | -9.13% 1112/2656 |
0.82% 1692/2280 |
-4.44% 1170/2385 |
0.95% 330/2515 |
-6.57% 1831/2655 |
| 2022 | -15.92% 439/2207 |
-10.90% 453/1919 |
6.85% 592/2016 |
-12.93% 808/2113 |
1.43% 1272/2208 |
| 2021 | -5.60% 979/1822 |
-2.60% 675/1255 |
1.08% 1067/1330 |
-6.03% 893/1466 |
2.03% 721/1822 |
| 2020 | 29.45% 537/1250 |
-9.94% 733/1028 |
11.68% 719/1067 |
14.33% 283/1164 |
12.58% 451/1184 |
| 2019 | 34.23% 412/1092 |
21.61% 597/754 |
4.11% 39/804 |
0.25% 540/850 |
5.75% 680/918 |
| 2018 | -16.96% 120/834 |
- - |
- - |
- - |
-11.49% 300/691 |
| 2017 | 27.25% 90/714 |
- - |
- - |
- - |
- - |
| 2016 | -2.57% 134/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.6144 | 32.25% |
| 景顺长城中证港股通创新药ETF | 1.6764 | 32.17% |
| 港股医疗 | 0.9539 | 31.90% |
| 港股医疗ETF | 1.4546 | 31.90% |
| 港股通医疗ETF工银 | 0.9639 | 31.81% |
| 港股通医疗ETF华宝 | 0.9752 | 31.64% |
| 万家中证港股通创新药ETF发起式联接A | 1.4069 | 31.06% |
| 万家中证港股通创新药ETF发起式联接C | 1.4061 | 30.98% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 嘉实中证港股通创新药指数发起式A | 0.8590 | 30.57% |
| 易方达上证50指数(LOF)A VS. 长安沪深300非周期A(740101) |